文献速递腹部技术与安全PETCT

18F-FDG PET/CT与碳水化合物抗原19-9对胰腺癌淋巴结微转移的预测价值

The value of 18F-FDG PET/CT and carbohydrate antigen 19-9 in predicting lymph node micrometastases of pancreatic cancer.
PubMed 文献 · Abdom Radiol (NY) · 2019-01-01

该研究纳入2012至2017年160例胰腺癌患者,术前行PET/CT及CA 19-9检测,与术后病理对照。原发灶SUVmax和CA 19-9是淋巴结状态的强预测因子,预测淋巴结微转移的最佳界值分别为SUVmax 7.05(敏感度71.2%、特异度76.6%)和CA 19-9 240.55 U/ml(敏感度62.1%、特异度79.8%)。

要点

  • 原发灶SUVmax≥7.05或CA 19-9≥240.55 U/ml的胰腺癌患者可能存在淋巴结微转移。
  • 预测淋巴结微转移的SUVmax最佳界值为7.05,敏感度71.2%、特异度76.6%。
  • 预测淋巴结微转移的CA 19-9最佳界值为240.55 U/ml,敏感度62.1%、特异度79.8%。

核心结论

  • 原发灶SUVmax和CA 19-9水平是判定胰腺癌淋巴结状态的强预测因子,SUVmax≥7.05或CA 19-9≥240.55 U/ml的患者可能存在淋巴结微转移。

研究设计与样本

  • 研究纳入2012至2017年160例胰腺癌患者,均接受手术治疗,术前行PET/CT扫描及CA 19-9检测,PET/CT由2名对临床信息不知情的核医学医师评估并与术后病理对照,采用Logistic回归分析确定预测淋巴结微转移的变量,并用ROC曲线寻找最佳界值。

诊断标准与关键数值

  • 预测淋巴结微转移的原发灶SUVmax最佳界值为7.05,敏感度71.2%、特异度76.6%;CA 19-9最佳界值为240.55 U/ml,敏感度62.1%、特异度79.8%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: This study aimed to assess the value of 18F-FDG PET/CT and carbohydrate antigen 19-9 (CA 19-9) levels in predicting lymph node micrometastases in patients with pancreatic cancer.

PATIENTS AND METHODS: A total of 160 patients with pancreatic carcinoma were included in the study from 2012 to 2017. All patients underwent surgical treatment and PET/CT scans as well as tests to measure CA 19-9 levels before surgery. The PET/CT scans were evaluated by 2 nuclear medicine physicians who were blinded to the clinical information and were compared to the postsurgical pathological findings. Logistic regression analysis was performed to determine the variables that could predict lymph node micrometastases. Receiver operating characteristic (ROC) curves were utilized to find the best cutoff value of the variables related to predicting lymph node micrometastases.

RESULTS: The maximum standardized uptake value (SUVmax) of the primary tumor and CA 19-9 level were potent predictors for determining the lymph node status. The best SUVmax and CA 19-9 cutoff values for predicting lymph node micrometastases were 7.05 (sensitivity = 71.2%, specificity = 76.6%) and 240.55 U/ml (sensitivity = 62.1%, specificity = 79.8%), respectively.

CONCLUSION: Patients with pancreatic cancer with a tumor SUVmax ≥ 7.05 or a CA 19-9 value ≥ 240.55 are likely to have lymph node micrometastases.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Wang S, Shi H, Yang F, et al. The value of 18F-FDG PET/CT and carbohydrate antigen 19-9 in predicting lymph node micrometastases of pancreatic cancer. Abdom Radiol (NY). 2019. PMID: 31570958. doi:10.1007/s00261-019-02248-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。